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Background: Venous Thrombo-embolic disease is currently a hot topic especially in the UK. 25,000 patients per
year die of Pulmonary Emboli (PE) in the United Kingdom (UK). Hip and knee arthroplasty surgery is associated with
an increased rate of deep vein thrombosis (DVT) and pulmonary embolus (PE). The National Institute for Clinical
Excellence (NICE) guidelines introduced in January 2010 recommended use of subcutaneous heparin or an oral
anticoagulant (Dabigatran or Rivaroxiban) for 10-14 days post knee and 28-35 days post hip arthroplasty. In our unit
we were keen on the advantages of an oral anticoagulant post arthroplasty in terms of patient compliance, and
avoiding the need for self administered injection in the community.
Methods: We analysed all the notes, blood results and imaging of patients undergoing total hip or knee
arthroplasty and present 1 year’s data using a regime of subcutaneous Dalteparin whilst an inpatient, followed by
discharge on oral Dabigatran at a low dose (150 mg once daily).
Results: There were 337 patients over 1 year with hip and knee arthroplasty, with a 1.19% rate of DVT with no PEs
and 1 death due to an unrelated cause. There was a transfusion rate of 11.57% with 1.19% patients taken back to
theatre for evacuation of haematomas. There were no reported adverse effects of Dabigatran.
Conclusion: Our treatment protocol is a novel practical approach for VTE prophylaxis in hip and knee replacement
patients. This approach shows promising data but no definitive evidence to warrant wide-spread use of this new
regime. This data can act as a foundation for larger randomised clinical trials.
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Venous thrombo-embolic (VTE) disease is currently an
important hot topic, especially in the United Kingdom.
In response to growing political pressures, including
alarming statistics such as 25,000 hospital deaths in
patients per year due to PEs in the UK [1], new NICE
guidelines were introduced in January 2010 for VTE
prophylaxis [2].
These guidelines recommended use of subcutaneous
low molecular weight heparin or an oral anticoagulant* Correspondence: drpad@hotmail.com
1North East Thames London orthopaedic rotation, Current hospital: Whipps
Cross Hospital, Whipps Cross Road, London E11 1NR, UK
Full list of author information is available at the end of the article
© 2012 Subramanian et al.; licensee BioMed C
Creative Commons Attribution License (http:/
distribution, and reproduction in any medium(Dabigatran Etexilate or Rivaroxiban) for 10-14 days post
knee arthroplasty and 28-35 days post hip arthroplasty.
It is recognised that hip and knee arthroplasty are asso-
ciated with an increased rate of VTE [2,3]. Our department
designed an anticoagulant prophylaxis regime in response
to these guidelines based on the following factors.
We were keen on the advantages of an oral anticoagu-
lant post hip or knee arthroplasty in terms of patient
compliance [4,5], and avoiding the need for self adminis-
tered injection in the community. Dabigatran Etexilate
(hereafter termed Dabigatran) has been tested in large
clinical trials and has been shown to have equivalent ef-
fectiveness to subcutaneous Enoxaparin, and to be simi-
lar in terms of safety and side effect profile [6-9].entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Bar chart demonstrating results with our protocol
versus those for pooled analyses from the major VTE trials [15].
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demonstrated that an increase in the risk of bleeding on
the day of surgery was associated with an increase in
Dabigatran peak concentration, hence supporting the
licenced protocol of halving the dose of Dabigatran on
the day of surgery [10]. Furthermore, anecdotally, there
were concerns with reference to wound discharge when
oral anticoagulants were used in the immediate post
operative period, so the decision was made to continue
with the subcutaneous anticoagulant we normally used
(Dalteparin 5000 units once daily) during the inpatient
stay, and to discharge the patient home on oral Dabigatran
for the remainder of the recommended timeframes.
There are two dosing levels of Dabigatran: 220 mg is
the standard dose, with a recommendation for patients
over the age of 75 years and/or ‘moderate’ renal failure
(creatinine clearance 30-50 ml/min), and/or patients on
concomitant Amiodarone and Verapamil, to have the
lower dose of 150 mg daily [11]. The decision was made
to use the low dose (150 mg) for all patients, as a large
proportion of our patients were either over the age of
75 years or had moderate renal impairment, and this
would simplify prescribing regimes for the high turnover
of departmental junior doctor staff. The aim of this
study therefore was to evaluate the outcomes of our
VTE protocol and compare the results to the published
literature.
Materials and methods
All patients undergoing primary hip or knee arthroplasty
between March 2010 and March 2011 were prescribed
the aforementioned regime post operatively (Dalteparin
5000 u subcutaneously whilst an inpatient, and Dabigatran
150 mg once daily orally on discharge for 14 days for knees
and 28 days for hips). The Dalteparin commenced the
evening of the day of surgery at 1800 for morning opera-
tions, and at 0800 the following morning for evening
operations.
Data concerning clinical DVT rate, clinical PE rate,
mortality, wound ooze/discharge, Haemoglobin (Hb)
drop, transfusion rate, infection rate and other complica-
tions was collected prospectively, and reviewed by an in-
dependent observer at 1 year. The patient population
was operated upon by 7 Consultants and 2 Associate
Specialists in a standard District General Hospital
(DGH) setting.
The types of implants (by individual surgeon prefer-
ence) were, for knees: Cemented Scorpio knees (Stryker,
Newbury, UK), Uncemented LCS knees (Depuy, Leeds,
UK). For the hips: Cemented Exeter (Stryker), and Unce-
mented Trident-Accolade (Stryker) or Uncemented Fur-
long (JRI Ltd, Sheffield, UK). All knee replacements had
a re-transfusion drain (Bellovac, Astra Tech Healthcare,
Gloucestershire UK) and received autotransfusion ifmore than 200 ml collected in the drain during the first
6 hours post operatively.
The following patients were excluded from this study on
the basis of bias or because these patients were contra-
indicated to receiving Dabigatran for thrombo-prophylaxis:
Patients on Warfarin preoperatively, Patients with bleeding
diathesis, patients requiring revision hip or knee arthro-
plasty, patients with deranged liver function tests (Liver
enzyme blood tests: Alanine transaminase, Alkaline phos-
phatase and Aspartate transaminase, which were greater
than 2 units above the upper normal limit), patients on
Quinidine and patients with renal failure with a creatinine
clearance of less than 30 ml/min. There were a total of 58
patients (14.7%) excluded from this study (40 were due to
revision arthroplasty).
To ensure all possible clinical thromboembolic events
were recorded, the hospital databases for the VTE clinic
(where all patients with DVT or PE are treated locally),
PACS radiology system for positive duplex and computer
tomography assisted pulmonary angiogram scans and
the electronic medical notes for all patients were all
reviewed by an independent observer (a qualified ortho-
paedic surgical trainee MBBS, MRCS). The data collec-
tion was complete.Results
We had a DVT rate overall of 1.19% (4 patients)
Figure 1. There were no PE’s. The majority of DVT’s oc-
curred in patients who had undergone THR’s, with a rate
of 1.96% (3 patients), and 1 patient in the TKR group
with a rate of 0.54%. Table 1 shows that a large propor-
tion of the DVT’s occurred in the cemented THR group
(2/57 cemented THR versus 1/96 uncemented THR),
this was not statistically significant (p = 0.67), chi squared

















TKR Uncemented 41 0 0 2.07 7.3 0 0 0
TKR Cemented 143 1 0.7 2.14 7.7 2.80 (n = 4) 2.80 (n = 4) 0.7 (n = 1)
THR Uncemented 96 1 1.04 2.82 13.5 0 0 1.04 (n = 1)
THR Cemented 57 2 3.51 2.81 21.1 0 1.75 (n = 1) 1.75 (n = 1)
* Hb = Haemoglobin.
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34.5 days post operatively with a range of 21 – 45 days.
The average haemoglobin drop for all patients was 2.46,
as measured the morning following surgery. Haemor-
rhagic events were classified into two categories: major
bleeds or clinically relevant non-major bleeds. Major
haemorrhage constituted events that led to death, bleed-
ing into critical organs, bleeding requiring a transfusion
of more than 2 units of blood or bleeding that required a
reoperation. Clinically relevant non major bleeds con-
sisted of minor haemorrhage from body orifices (epistaxis,
per rectal bleeding, macroscopic haematuria, wound hae-
matomas that did not require reoperation) [12].
By these definitions there were 5 patients who suffered
a major haemorrhage. There were 4 in the cemented
TKR group that had to return to theatre for a haemar-
throsis. The one patient in the cemented THR group
who suffered a major haemorrhage required a transfu-
sion of more than 7 units of blood products intraopera-
tively and was not therefore a consequence of VTE
chemoprophylaxis.
The transfusion rates are set out in Table 1. With re-
spect to the TKR’s who had a reperfusion drain, the
transfusion rate referred to is not autotransfusion from
their drain, but allogenic blood.
No THRs were taken back to theatre for haematoma or
wound discharge. However 4 TKRs required washout for
haemarthrosis. It is worth noting that none of these 4
patients taken back to theatre were being treated on
Dabigatran at the time of developing a haematoma. There
were no cases of deep infection. There was one death in
our study. This patient had a cemented THR and died
13 months post operatively from a myocardial infarction.
On statistical testing (chi squared, SPSS) there was no
statistically significant difference between total hip or total
knee replacement subgroups in terms of transfusion rate
(p= 0.09), return to theatre rate (p= 0.97) or those suffer-
ing a clinically relevant major bleed (p= 0.57).
Discussion
The subject of VTE and prophylaxis became a national
issue in January of 2010 when NICE released a document
with prophylaxis algorithms for hospital patients, includ-
ing sections specifically relating to lower limb arthroplasty[2]. Rightly or wrongly numerous orthopaedic depart-
ments found themselves having to alter their prophylactic
regimes on the basis of this document, particularly to
comply with the recommendations for anticoagulation to
continue for 10-14 days post knee, and 28-35 days post
hip arthroplasty.
Previously numerous anticoagulant regimes ceased on
discharge of the patient, around day 5 post operatively
[5,13,14]. One of the NICE recommended anticoagu-
lants was Dabigatran Etexilate (Boehringer Ingelheim),
which is an oral direct thrombin inhibitor. It had been
the subject of large European multicentre trials
(RENOVATE, REMODEL, REMOBILIZE) and had
been demonstrated to be equivalent to subcutaneous
Enoxaparin both in terms of clinical effectiveness and
safety [7-9,15].
Three major prospective, randomized, double-blind
non-inferiority trials have compared the efficacy and
safety of Dabigatran (150 mg and 220 mg once-daily)
starting postoperatively, with subcutaneous Enoxaparin,
in patients undergoing hip (RE-NOVATE [6]) or knee
arthroplasty (RE-MOBILIZE [9] and RE-MODEL [8]). In
the RE-MODEL and RE-NOVATE trials, both doses of
Dabigatran were as effective as Enoxaparin 40 mg once
daily in reducing the risk of total VTE and all-cause
mortality after hip [6] or knee arthroplasty [8]. Pooled
analysis of major bleeding and the clinically relevant
non-major bleeding indicated a similar bleeding profile
with each Dabigatran dose, which was comparable with
Enoxaparin [15]. The overall bleeding risk in patients
older than 75 years and in patients with moderate renal
impairment (Creatinine clearance >30 to <50 ml/min)
was lower in the 150 mg subgroups compared with ei-
ther 220 mg Dabigatran or Enoxaparin.
Friedman et al conclude that the pooled analysis of the
three major prospective trials revealed no clinically rele-
vant differences between Dabigatran at the 150 mg or
220 mg dosage regimes and Enoxaparin for the preven-
tion of major VTE and VTE related mortality or for the
safety profile [15] Figure 1.
In arthroplasty surgery there has always been a trade-
off between the VTE prophylactic effects of anticoagu-
lants versus reported increase in wound discharge, with
the added concern that wound discharge potentially
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sents an unmitigated disaster in terms of outcome of the
arthroplasty [17].
At the time of inception of our new protocol there
were anecdotal reports from colleagues of increased pro-
blems of wound discharge post arthroplasty when
Dabigatran was used exclusively. It was for this reason
(supported by data from dose selection studies showing
increased risk of bleeding on the day of surgery asso-
ciated with Dabigatran [10]) that we decided to con-
tinue with our standard subcutaneous anticoagulant
(Dalteparin) in the immediate post operative period, and
not to prescribe Dabigatran until discharge, by which time
the surgical wound had dried up (our patients are not dis-
charged home until the dressing has been dry for 24 hours
as a matter of departmental policy). It should be noted
that our policies do not significantly alter lengths of stay
of the patients. The results from this study illustrate our
length of stay for patients post total hip and total knee re-
placement is 4.6 and 4.7 days respectively. This compares
favourably with other studies in terms of short lengths of
stay [18].
The benefits of an oral anticoagulant on discharge are
self evident when compared to self administered sub-
cutaneous injections, given the choice one would always
choose the oral medication, all other factors remaining
equal. Patient compliance is greater [4,5], and one can
postulate the VTE prophylactic effect for ones patient
population will be greater if they are actually taking the
medicine.
Furthermore, Dabigatran has the advantage over low
molecular weight heparins in that thus far there are no
reported cases of significant allergic reactions to taking
the medication, nor is there the risk of developing heparin
induced thrombocytopenia, therefore negating the need
for blood tests during the period of chemoprophylaxis.
Dabigatran comes with 2 dosage recommendations,
the standard dose of 220 mg, and a lower dose for any-
one over the age of 75 or with mild impairment of renal
function (creatinine clearance 30-50 ml/min) [11]. This
appeared to add a layer of complication for junior doctor
prescription of discharge medication, with the scope for
error. The decision was made therefore to prescribe the
lower dose of 150 mg once daily to all patients for
prophylaxis. A large proportion of our patients for
arthroplasty are aged 75 years or over, and/or have a de-
gree of mild renal impairment, so this seemed a sensible
course of action.
This is a potentially controversial decision, because,
despite the fact that the trials include a significant pro-
portion of their patients being treated with the lower
dose, they are all in the elderly or mildly renal impaired
group, and the decision to treat all-comers on the lower
dose could be considered in some ways to be an ‘off-licence’ use of the medication. The pooled analysis of
the multicentre trials conclude that there are no clini-
cally relevant differences between Dabigatran (220 mg or
150 mg) and Enoxaparin for the prevention of VTE or
for the safety profile [15].
For the return to theatre for the washout of haema-
toma, two patients were on Dalteparin at the time. The
other two cases were 23 and 64 days post operatively
when they had finished treatment with Dabigatran. It
should be noted that patients were on Dalteparin when
the haemoglobin drop and transfusion rates were mea-
sured and Dabigatran had not yet been started. Our
transfusion rates for TKR and THR are 7.6% and 16.3%
respectively. The overall average transfusion rate is
11.6%. This is below quoted figures from other studies
including Bell et al [19]. They report an overall 22% rate of
transfusion in arthroplasty surgery when using Dalteparin
for VTE prophylaxis. Other studies quote transfusion
figures as high as 39%. This could be due to including
patients undergoing revision surgery which are more likely
to require blood transfusions.
There are some limitations to our study. It should be
noted that it is assumed that patients who are prescribed
the Dabigatran take the full course of medication and
compliance has not actually been checked. It should be
noted as mentioned earlier, one of the advantages of oral
medication is improved compliance in taking the medi-
cation amongst patients. We do however feel that our
protocol has promising results with valuable data and
provides a growing body of evidence to the new oral
anticoagulant and warrants further evaluation.Conclusion
Our treatment protocol is a novel practical approach for
VTE prophylaxis in hip and knee replacement patients,
combining subcutaneous Heparin in hospital with oral
Dabigatran Etexilate after discharge. This approach
shows promising data but no definitive evidence to war-
rant wide-spread use of this new regime. This data can
act as a foundation for larger randomised clinical trials.
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